Rubric Capital Management LP
Rubric Capital Management LP's purchase track record
How the stock did after each of Rubric Capital Management LP's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/8/2025 | HRTX | $3.58M | -16.7% | -4.5% | +8.5% |
| 12/7/2022 | TXMD | $206K | -22.3% | -33.9% | +8.5% |
| 10/28/2022 | TXMD | $7.00M | -10.4% | -40.6% | +6.9% |
| 9/30/2022 | TXMD | $7.00M | -15.8% | -43.5% | +14.6% |
| 7/29/2022 | TXMD | $15.00M | -4.3% | -14.3% | -1.5% |
| 7/15/2022 | TXMD | $467K | +8.4% | -9.1% | +3.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CIBC initiates coverage on Talen Energy with $499 target. CIBC has started covering Talen Energy, assigning an Outperformer rating and a price target of $499. This new analyst view comes as the company prepares to report its third-quarter financial results on November 3, 2026. The stock is currently trading within its 52-week range, with recent activity highlighting its position relative to key support levels.
Transaction History
| HRTX | ▼ Sell | Other | 946,100 | — | 10/15/2025 | View on chart |
| COLL | ▼ Sell | Open Market | 25,000 | $946K | 8/13/2025 | View on chart |
| HRTX | ▲ Buy | Open Market | 2,387,225 | $3.6M | 8/8/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 12,290 | $3.6M | 6/27/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 7,950 | $2.3M | 6/27/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 2,365 | $694K | 6/27/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 51,810 | $15.3M | 6/27/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 76,545 | $22.7M | 6/27/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 25,903 | $7.7M | 6/27/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 1,137 | $339K | 6/27/2025 | View on chart |
| TLN | ▼ Sell | Other | 1,281,839 | — | 6/27/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 100 | $29K | 6/26/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 1,321 | $382K | 6/26/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 18,927 | $5.5M | 6/26/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 15,824 | $4.6M | 6/26/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 33,121 | $9.7M | 6/26/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 32,924 | $9.7M | 6/26/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 44,343 | $12.8M | 6/25/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 6,429 | $1.9M | 6/25/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 200 | $58K | 6/25/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 16,759 | $4.9M | 6/25/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 21,552 | $6.3M | 6/25/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 13,973 | $4.1M | 6/25/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 4,957 | $1.5M | 6/25/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 100 | $30K | 6/25/2025 | View on chart |
| TLN | ▼ Sell | Open Market | 4,893,507 | $1000.0M | 12/13/2024 | View on chart |
| TLN | ▼ Sell | Other | 351,607 | — | 12/13/2024 | View on chart |
| TXMD | ▲ Buy | Grant | 877,192 | $2.0M | 11/15/2023 | View on chart |
| TXMD | ▲ Buy | Grant | 312,525 | $1.1M | 6/28/2023 | View on chart |
| TXMD | ▼ Sell | Open Market | 29,000 | $38.7M | 12/30/2022 | View on chart |
| TXMD | ▲ Buy | Open Market | 14,825 | $90K | 12/9/2022 | View on chart |
| TXMD | ▲ Buy | Open Market | 300 | $2K | 12/8/2022 | View on chart |
| TXMD | ▲ Buy | Open Market | 20,113 | $114K | 12/7/2022 | View on chart |
| TXMD | ▲ Buy | Open Market | 7,000 | $7.0M | 10/28/2022 | View on chart |
| TXMD | ▲ Buy | Open Market | 7,000 | $7.0M | 9/30/2022 | View on chart |
| TXMD | ▲ Buy | Open Market | 565,000 | $2.7M | 7/29/2022 | View on chart |
| TXMD | ▲ Buy | Open Market | 15,000 | $12.3M | 7/29/2022 | View on chart |
| TXMD | ▲ Buy | Open Market | 17,688 | $107K | 7/18/2022 | View on chart |
| TXMD | ▲ Buy | Open Market | 64,892 | $361K | 7/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Heron Therapeutics Signs U.S. License Deal
Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.
Heron Therapeutics Signs U.S. License Deal. Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.